Thursday , 18 October 2018
Breaking News
Home » Tag Archives: genocore

Tag Archives: genocore

Genocore-Biotech.com Announce License Agreement to Develop Novel Inhibitor of Vascular Protein

logo Genocore-Biotech-com

Shenzhen; 28, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced an agreement for the further development of a novel, oral small molecule inhibitor of Vascular Protein 1, a cell molecule that may be effective in the treatment of inflammatory diseases. The inhibitor is ... Read More »

Genocore-Biotech.com Foundation Announces $250.000 Gift to Biotechnology Center

logo Genocore-Biotech-com

Shenzhen; 26, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced it has awarded a $250.000 Transformational Grant in Science Education to the Biotechnology Center to support the expansion of the Center’s educational training facility for science teachers. The grant is part of the Genocore Biotech Foundation’s new ... Read More »

Genocore-Biotech.com Appoints Hon Wen Long, M.D., to Scientific Advisory Board

logo Genocore-Biotech-com

Shenzhen; 26, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody, today announced that the company has appointed HonWen Long, M.D., to its Scientific Advisory Board. Dr. Wen Long is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders.Currently Dr. Wen Long is Professor of Psychiatry, Neurology & Medicine. ... Read More »

Genocore-Biotech.com Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial

logo Genocore-Biotech-com

23, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced that they plan to advance the companies’ Hemophilia B therapy a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a pharmacokinetic study in severe, previously-treated hemophilia B ... Read More »

Genocore-Biotech.com and Top Pharmaceutical Research Company Announce Collaboration Agreement to Develop and Commercialize Multiple Sclerosis Therapy (MST)

Shenzhen; 22, December 2015: Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced that they have entered into an exclusive collaboration and license agreement to develop and commercialize a multiple sclerosis (MS) therapy. The therapy is a novel, oral sustained-release compound being developed to improve walking ... Read More »